Literature DB >> 6849751

The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol.

M D Fernandez, G D Carter, T N Palmer.   

Abstract

1 Canrenone, the major active metabolite of spironolactone, decreased [3H]-progesterone binding to isolated uterine cytosolic progesterone receptors. The inhibition was concentration-dependent. 2 Canrenone did not alter [3H]-oestradiol binding to isolated uterine cytosolic oestrogen receptors. 3 Canrenone inhibition of progesterone binding to isolated cytosolic receptors was strictly competitive: Kd (apparent dissociation constant for progesterone binding) was increased in a concentration-dependent manner by canrenone, whereas Bmax (maximal number of progesterone binding sites/mg cytosolic protein) was unaltered. There was marked cooperativity in progesterone binding at high canrenone and low progesterone concentrations. The implication is that canrenone alters the subunit interaction of the receptor protein. 4 Kd for progesterone was 3.2 X 10(-9)M. Ki (the inhibition constant for canrenone with respect to progesterone binding) was 300 X 10(-9)M. Reports in the literature suggest that, following spironolactone administration, canrenone may rise to concentrations sufficiently high to inhibit progesterone binding. This action may contribute to the effect of spironolactone in inducing menstrual disturbances in female patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849751      PMCID: PMC1427833          DOI: 10.1111/j.1365-2125.1983.tb01470.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  SPIRONOLACTONE THERAPY AND GYNECOMASTIA.

Authors:  E CLARK
Journal:  JAMA       Date:  1965-07-12       Impact factor: 56.272

2.  Screening for anti-hormones by receptor studies.

Authors:  J P Raynaud; C Bonne; M M Bouton; M Moguilewsky; D Philibert; G Azadian-Boulanger
Journal:  J Steroid Biochem       Date:  1975-05       Impact factor: 4.292

3.  Antiandrogenic effect of spirolactones: mechanism of action.

Authors:  P Corvol; A Michaud; J Menard; M Freifeld; J Mahoudeau
Journal:  Endocrinology       Date:  1975-07       Impact factor: 4.736

Review 4.  Spironolactone.

Authors:  H R Ochs; D J Greenblatt; G Bodem; T W Smith
Journal:  Am Heart J       Date:  1978-09       Impact factor: 4.749

5.  Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors.

Authors:  J W Funder; D Feldman; E Highland; I S Edelman
Journal:  Biochem Pharmacol       Date:  1974-05-15       Impact factor: 5.858

6.  Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism.

Authors:  R H Menard; B Stripp; J R Gillette
Journal:  Endocrinology       Date:  1974-06       Impact factor: 4.736

7.  Mode of spirolactone action: competitive inhibition of aldosterone binding to kidney mineralocorticoid receptors.

Authors:  D D Fanestil
Journal:  Biochem Pharmacol       Date:  1968-10       Impact factor: 5.858

8.  Gynecomastia induced in normal males by spironolactone.

Authors:  D H Huffman; J P Kampmann; C E Hignite; D L Azarnoff
Journal:  Clin Pharmacol Ther       Date:  1978-10       Impact factor: 6.875

9.  Spironolactone. I. Disposition and metabolism.

Authors:  A Karim; J Zagarella; J Hribar; M Dooley
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

10.  Spironolactone and canrenoate-K: relative potency at steady state.

Authors:  L Ramsay; M Asbury; J Shelton; I Harrison
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

View more
  2 in total

Review 1.  Hirsutism and the effectiveness of spironolactone in its management.

Authors:  G R McMullen; A J Van Herle
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

2.  Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI.

Authors:  C Sabbadin; A Andrisani; M Zermiani; G Donà; L Bordin; E Ragazzi; M Boscaro; G Ambrosini; D Armanini
Journal:  J Endocrinol Invest       Date:  2016-04-12       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.